ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
101,002.39
0.34%
S&P 500
6,040.53
-0.50%
Dow Jones
44,544.66
-0.75%
US Dollar vs Yen
155.195
-0.01%
Brent Oil
76.385
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Atossa Therapeutics Inc (ATOS) 銘柄情報

Atossa Therapeutics Inc

Atossa Therapeutics Inc (ATOS)

NASDAQ
0.8419
-0.0234
(-2.70%)
終了 2月2日 6:00AM
15分遅延
0.8201
-0.0218
(-2.59%)
取引時間後: 9:40AM
15分遅延

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

主要統計と詳細

通貨
0.8201
買値
0.82
売値
0.862
出来高
710,557
0.8299 日の範囲 0.9179
0.7203 52 週間の範囲 2.31
時価総額
103.17M
前日終値
0.8653
始値
0.88
時刻
4
@
0.8599
最終取引時間
財務取引量
US$ 620,613
VWAP
0.873418
平均取引量 (3 か月)
905,318
発行済株式数
125,801,254
配当利回り
-
PER
-3.51
1 株当たり利益 (EPS)
-0.24
歳入
-
純利益
-30.09M

Atossa Therapeutics Inc について

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
www.atossatherapeutics.com
本社
Wilmington, Delaware, USA
設立
-
Atossa Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ATOS. The last closing price for Atossa Therapeutics was US$0.87. Over the last year, Atossa Therapeutics shares have traded in a share price range of US$ 0.7203 to US$ 2.31.

Atossa Therapeutics currently has 125,801,254 shares in issue. The market capitalisation of Atossa Therapeutics is US$108.86 million. Atossa Therapeutics has a price to earnings ratio (PE ratio) of -3.51.

ATOS 最新ニュース

その他のニュース

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

2025年1月30日
GlobeNewswire Inc.

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

2025年1月23日
GlobeNewswire Inc.

Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and...

2025年1月6日
GlobeNewswire Inc.

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

2024年12月12日
GlobeNewswire Inc.

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session...

2024年12月11日
GlobeNewswire Inc.

Form 8-K - Current report

2024年12月10日
Edgar (US Regulatory)

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

2024年12月10日
GlobeNewswire Inc.

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

SEATTLE, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

2024年12月9日
GlobeNewswire Inc.

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that a poster detailing the anti-cancer activity of...

2024年11月21日
GlobeNewswire Inc.

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in...

2024年11月20日
GlobeNewswire Inc.
期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.1099-11.81720430110.930.970.72037926850.87458321CS
4-0.1689-17.07785642060.9891.040.72038303630.89568254CS
12-0.6699-44.95973154361.491.660.72039053181.09976417CS
26-0.5699-411.391.660.72036933971.22509247CS
52-0.0209-2.485136741970.8412.310.720310304051.41299611CS
156-0.4099-33.3252032521.232.310.58999371.18189219CS
260-0.6299-43.44137931031.459.80.535765123.14762667CS

ATOS - Frequently Asked Questions (FAQ)

What is the current Atossa Therapeutics share price?
The current share price of Atossa Therapeutics is US$ 0.8201
How many Atossa Therapeutics shares are in issue?
Atossa Therapeutics has 125,801,254 shares in issue
What is the market cap of Atossa Therapeutics?
The market capitalisation of Atossa Therapeutics is USD 108.86M
What is the 1 year trading range for Atossa Therapeutics share price?
Atossa Therapeutics has traded in the range of US$ 0.7203 to US$ 2.31 during the past year
What is the PE ratio of Atossa Therapeutics?
The price to earnings ratio of Atossa Therapeutics is -3.51
What is the reporting currency for Atossa Therapeutics?
Atossa Therapeutics reports financial results in USD
What is the latest annual profit for Atossa Therapeutics?
The latest annual profit of Atossa Therapeutics is USD -30.09M
What is the registered address of Atossa Therapeutics?
The registered address for Atossa Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Atossa Therapeutics website address?
The website address for Atossa Therapeutics is www.atossatherapeutics.com
Which industry sector does Atossa Therapeutics operate in?
Atossa Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
731.1M
REBNReborn Coffee Inc
US$ 3.31
(63.05%)
55.54M
FCUVFocus Universal Inc
US$ 5.87
(56.62%)
1.73M
SOPASociety Pass Inc
US$ 1.54
(56.50%)
13.87M
CYCNCyclerion Therapeutics Inc
US$ 3.92
(54.33%)
82.57M
ENVBEnveric Biosciences Inc
US$ 2.0899
(-46.41%)
1.57M
NIVFNewGenIvf Group Ltd
US$ 0.1489
(-42.51%)
14.8M
GLSTGlobal Star Acquisition Inc
US$ 8.83
(-39.10%)
23.89k
PRPHProPhase Labs Inc
US$ 0.2633
(-38.02%)
872.46k
SPGCSacks Parente Golf Inc
US$ 0.5601
(-37.86%)
7.27M
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
729.72M
NVDANVIDIA Corporation
US$ 120.07
(-3.67%)
388.54M
RIMEAlgorhythm Holdings Inc
US$ 0.02565
(5.12%)
338.75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0355
(-11.25%)
236.29M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1938
(30.77%)
234.8M

ATOS Discussion

投稿を表示

最近閲覧した銘柄

NASDAQ
ATOS
Atossa Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す